Improving Confidence in Thyroid Hormone Disruption Assessment Using a Novel Human-Relevant In Vitro Model
Learn how an emerging NAM is helping advance more efficient, human-relevant strategies for assessing thyroid hormone disruption while reducing reliance on animal testing.
Non CYP Mediated Metabolism Pathways and In Vitro Evaluation Strategies
Discover non-CYP metabolism pathways, key enzymes, and in vitro strategies for safer drug development in this webinar.
Improved Clearance Predictions for Aldehyde Oxidase Substrates Using TruVivo, a Novel Human Hepatocyte Model
In this exclusive session, Stephanie Piekos, PhD, Senior Scientist at Boehringer Ingelheim, shares insights into the challenges of evaluating AO substrates and how more predictive, human-relevant models are shaping the future of DMPK studies.
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
#ExpertAnswers: Jack Vanden Heuvel on Prediction Drug-Drug Interactions Early
Dr. Jack Vanden Heuvel from Penn State University and INDIGO Biosciences answers questions from a recent webinar where he discusses [...]
How to Better Predict Potential Drug Interactions Early in the Discovery Process
Dr. Jack Vanden Heuvel answers questions about the prediction of drug-drug interactions using in vitro assays and gene expression studies.
How to Better Predict Potential Drug Interactions Early in the Discovery Process
Join our webinar to discover effective strategies for early prediction of drug-drug interactions using in-vitro assays and gene expression studies.
Evaluation of TruVivo, an All-Human Hepatocyte Model for Mechanistic DMPK Investigations
Join Diane Ramsden, PhD, and Lindsey Whaley, MS, for an inside look at TruVivo™, a novel all-human in vitro hepatocyte system developed by LifeNet Health LifeSciences.
#ExpertAnswers: Audrey Dubourg and Gareth Guenigault on the Organ-On-A-Chip Approach
Audrey Dubourg and Gareth Guenigault from CN Bio discuss the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
#ExpertAnswers: Andrew Taylor on Drug Metabolism
Andrew Taylor provides an overview of processes by which drugs are metabolized and talks about the importance of drug metabolism and drug-drug interaction studies.
It’s Life, but Not As We Know It: How Predictive Human Organ Models Are Transforming and Reshaping the Efficiency of Drug Discovery
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Are In Vitro Metabolism and Drug-Drug Interaction Studies Critical for an Investigational New Drug Application?
Andrew G. Taylor, PhD provides an overview of processes by which drugs are metabolized and discusses the importance of drug metabolism and drug-drug interaction studies.
